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CHRONIC OBSTRUCTIVE PULMONARY DISEASE
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Background: Ongoing inflammatory processes resulting in airway and vascular remodelling characterise
chronic obstructive pulmonary disease (COPD). Vascular endothelial growth factor (VEGF) and its
receptors VEGFR-1 (Flt-1) and VEGFR-2 (KDR/Flk-1) could play a role in tissue remodelling and
angiogenesis in COPD.
Methods: The cellular expression pattern of VEGF, Flt-1, and KDR/Flk-1 was examined by
immunohistochemistry in central and peripheral lung tissues obtained from ex-smokers with COPD
(forced expiratory volume in 1 second (FEV1) ,75% predicted; n = 14) or without COPD (FEV1 .85%
predicted; n = 14). The immunohistochemical staining of each molecule was quantified using a visual
scoring method with grades ranging from 0 (no) to 3 (intense).
Results: VEGF, Flt-1, and KDR/Flk-1 immunostaining was localised in vascular and airway smooth muscle
(VSM and ASM) cells, bronchial, bronchiolar and alveolar epithelium, and macrophages. Pulmonary
endothelial cells expressed Flt-1 and KDR/Flk-1 abundantly but not VEGF. Bronchial VEGF expression was
higher in microvascular VSM cells and ASM cells of patients with COPD than in patients without COPD
(1.7 and 1.6-fold, p,0.01, respectively). VEGF expression in intimal and medial VSM (1.7 and 1.3-fold,
p,0.05) of peripheral pulmonary arteries associated with the bronchiolar airways was more intense in
COPD, as was VEGF expression in the small pulmonary vessels in the alveolar region (1.5 and 1.7-fold,
p,0.02). In patients with COPD, KDR/Flk-1 expression was enhanced in endothelial cells and in intimal
and medial VSM (1.3, 1.9 and 1.5-fold, p,0.02) while endothelial Flt-1 expression was 1.7 times higher
(p,0.03). VEGF expression was significantly increased in bronchiolar and alveolar epithelium as well as
in bronchiolar macrophages (1.5-fold, p,0.001). The expression of VEGF in bronchial VSM and mucosal
microvessels as well as bronchiolar epithelium was inversely correlated with FEV1 (r,20.45; p,0.01).
Conclusions: VEGF and its receptors Flt-1 and KDR/Flk-1 may be involved in peripheral vascular and
airway remodelling processes in an autocrine and/or paracrine manner. This system may also be
associated with epithelial cell viability during airway wall remodelling in COPD.
C
hronic obstructive pulmonary disease (COPD) is a
disease state characterised by airflow limitation that
is not fully reversible, usually progressive, and asso-
ciated with an abnormal inflammatory response of the lungs
in response to noxious particles and gases.1 COPD is a major
health problem with cigarette smoking as its main cause. One
important pathological feature of COPD is chronic airway
inflammation characterised by an influx of inflammatory
cells—predominantly neutrophils, macrophages and CD8+ T
lymphocytes—in the lumen and wall of the bronchial and
bronchiolar airways and parenchyma.2–4 Furthermore, several
studies have reported a thickened bronchiolar wall and
airway remodelling with peribronchiolar fibrosis, an increase
in airway smooth muscle (ASM) mass, and emphysema.3 5 6
Vascular abnormalities have been associated with the
development of COPD.7 8 Wright et al found an increase in
wall area of small (,500 mm) pulmonary vessels by intimal
thickening in patients with mild to moderate COPD and
medial thickening in severe cases as well, which was
correlated with a decline in forced expiratory volume in
1 second (FEV1).
7 9 Furthermore, recent observations have
indicated that muscular pulmonary and bronchiolar arteries
have increased adventitial infiltration of CD8+ T lymphocytes
and have intimal thickening that is correlated with the
amount of total collagen deposition.8 10 In addition, emphy-
sema may lead to loss of the pulmonary vascular bed and
induce angiogenesis.11 Little is known, however, about the
molecular mechanisms underlying these processes in the
context of COPD.
One of the potent proteins involved in vascular remodelling
is vascular endothelial growth factor (VEGF). The VEGF
family currently comprises six members (VEGF-A to F), of
which the originally identified VEGF-A165 variant is the
predominant form of five additional spliced variants.12 VEGFs
are heparin binding proteins and act via their high affinity
transmembrane receptors VEGFR-1 (Flt-1) and VEGFR-2
(KDR/Flk-1). The receptors belong to the family of tyrosine
kinases and are predominantly expressed by endothelial and
epithelial cells.12 VEGF promotes an array of responses in the
endothelium including hyperpermeability, endothelial cell
proliferation, and angiogenesis with new vessel tube forma-
tion in vivo.12 13 VEGF expression can be induced under a
number of pathophysiological conditions including pulmon-
ary hypoxia and pulmonary hypertension with increased
sheer stress.13 14 Both hypoxia and pulmonary hypertension
are pathological features often seen in patients with
advanced COPD.2 We hypothesise that increased VEGF
Abbreviations: ASM, airway smooth muscle; COPD, chronic
obstructive pulmonary disease; FEV1, forced expiratory volume in
1 second; TGF-b1, transforming growth factor b1; VEGF, vascular
endothelial growth factor; VSM, vascular smooth muscle
106
www.thoraxjnl.com
 on 25 October 2006 thorax.bmjjournals.comDownloaded from 
expression, perhaps under the influence of hypoxia inducible
transcription factors, may contribute to increased and
abnormal proliferation of endothelial and vascular smooth
muscle (VSM) cells in pulmonary vessels leading to vascular
remodelling.
Although the role of VEGF in the vascular biology has been
studied thoroughly, it has become clear that VEGF and its
receptor system are also involved in various other cellular
events including epithelial proliferation and survival and the
recruitment of mast cells, neutrophils, and macrophages to
sites of fibrosis.13 15 16 Recent studies indicate that VEGF is
expressed in the lung by bronchiolar, submucosal, glandular
and alveolar type I and II epithelial cells, alveolar macro-
phages, ASM and VSM cells, as well as myofibroblasts in
fibrotic lung lesions.14 17 18
In order to assess the role of VEGF and its receptors
VEGFR-1 (Flt-1) and VEGFR-2 (KDR/Flk-1) in the patho-
physiology of COPD, we first examined the expression of
VEGF-A, Flt-1, and KDR/Flk-1 in central and peripheral lung
tissue from ex-smokers with or without COPD. We also
investigated the relationship of lung function with the
expression of VEGF and its receptors.
METHODS
Selection of patients
Central and peripheral lung tissues were obtained from
current or ex-smokers undergoing lobectomy or pneumo-
nectomy for lung cancer. Fourteen subjects with COPD (FEV1
,75% predicted) and 14 subjects without COPD (FEV1 .84%
predicted) were included as previously described.19–21 23 Total
lung capacities (TLC) were not below normal levels (TLC
.80% predicted). None of the patients had an upper
respiratory tract infection and they did not receive antibiotics
perioperatively. No patients had received glucocorticosteroids
during the 3 month period before resection; four patients
received glucocorticosteroids perioperatively. Based on all
these criteria, subjects with COPD could not be subdivided
into patients with either chronic bronchitis or emphysema
alone. Clinical data are given in table 1. Subjects were
excluded if the obstruction of the central bronchi was due to
the tumour, if diffuse pulmonary inflammation or fibrosis
was present, or if no tissue free from tumour could be
obtained. The patients in the two groups had participated in a
larger research project, part of which has been published
previously.19–21 The medical ethics committee of LUMC
approved the study.
The lung tissue specimens used in this study were obtained
from the archival collection at the Department of Pathology
(LUMC, Leiden, NL). The specimens were routinely fixed in
10% neutral buffered formalin by inflation-immersion fixa-
tion and embedded in paraffin for histopathological exam-
ination and immunohistochemistry.
Immunohistochemistry
Paraffin sections (4 mm thick) of the lung tissues were cut
and mounted on silane coated glass slides. Immuno-
histochemistry was performed using a method described
elsewhere.20 22 23 Briefly, after deparaffinisation in xylene and
rehydration through graded alcohol, the slides were rinsed
with phosphate buffered saline (PBS). Endogenous perox-
idase was blocked with 0.3% hydrogen peroxidase. For VEGF,
VEGFR-1, VEGFR-2 and Ki-67 staining, slides were pre-
treated by boiling in citrate buffer (10 mM, pH=6.0) for
10 minutes in a microwave oven. The sections were
preincubated with 10% normal goat serum diluted in 5%
bovine serum albumin (BSA) in PBS (pH=7.4) and then
incubated for 30 minutes at room temperature with affinity
purified rabbit polyclonal VEGF antibody in a dilution of
1:200 v/v. The VEGF antibody used was raised against a 20
amino acid synthetic peptide corresponding to residues 1–20
of the amino terminus of human VEGF (Santa Cruz
Biotechnology Inc, Santa Cruz, CA, USA). A different series
of slides was incubated with a rabbit polyclonal antibody
against a synthetic peptide corresponding to aa 1312–1328 of
human Flt-1 (Neomarkers RB-1526, Fremont, CA, USA) in a
dilution of 1:100 v/v. For VEGFR-2, a rabbit polyclonal
antibody against amino acids 1326–1345 of mouse KDR/
Flk-1 (Neomarkers RB-1527) in a dilution of 1:200 v/v was
used. To examine proliferation of cells in the airways an
antibody against Ki-67 (Dako Corporation, Glostrup,
Denmark) of 1:400 v/v at 4oC overnight was used as a
marker. Consecutive tissue sections were also stained with a
monoclonal mouse anti-human alpha-smooth muscle actin
(a-SMA) antibody (clone 1A4; Biogenex, San Ramon, USA)
in a dilution of 1:1000 v/v. The optimal dilution of the first
antibody was identified by examining the intensity of
staining obtained with a series of dilutions of the antibody
from 1:50 to 1:1000. Negative controls were prepared by
omission of the primary antibody.
After washing with Tris-base buffered saline (TBS,
pH=7.4) the test and control slides were incubated for
15 minutes with Powervision post-antibody blocking solu-
tion (Immunovision Technologies, Daly City, CA, USA). The
slides were then washed and incubated with Powervision
polymerised horseradish peroxidase conjugates (Immuno-
vision Technologies) and the sections were stained with 3,39-
diaminobenzidine tetrahydrochloride (Sigma, Zwijndrecht,
NL) as chromogen, counterstained with Mayer’s haema-
toxylin, and visualised with light microscopy.
Quantitative scoring analysis of
immunohistochemistry
Before screening, sections were coded so that the observers
were unaware of the clinical details of the case under study.
Expression of VEGF, Flt-1, and KDR/Flk-1 was analysed
semiquantitatively using a visual scoring method with grades
ranging from 0 to 3 (0=no staining; 1=moderate staining;
2= intense staining; 3=very intense staining) as previously
described.8 19 20 23 The entire section of a tissue block was
investigated and scored at the same magnification. The
staining intensity of VEGF, Flt-1, and KDR/Flk-1 in the
bronchial and bronchiolar airways as well as the alveolar
parenchyma was scored blindly by two independent obser-
vers who were unaware of the clinical data of the case under
Table 1 Clinical characteristics of study subjects
Group Sex (M/F) Age
Smoking
(pack years)
FEV1
(% predicted)
FEV1/FVC
(%)
Steroid
treatment
Non-COPD 10/4 64 (3.7) 42 (7.7) 101 (3.3) 0.72 (0.02) None
COPD 14/0 64 (2.3) 44 (0.8) 63 (2) 0.54 (0.02) 4
p value 0.84 0.82 ,0.001 ,0.001
Data shown as mean (SD) values.
COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 second, FVC, forced vital
capacity.
Role of VEGF in COPD 107
www.thoraxjnl.com
 on 25 October 2006 thorax.bmjjournals.comDownloaded from 
study. Errors within and between observers were examined
by correlating the expression scores using Pearson’s analysis
and a very high correlation ranging from 0.8 to 0.9 was
obtained.
In the bronchial airways staining was assessed in the
bronchial epithelium, mucosal microvasculature, submucosal
bronchial wall vessels, ASM cells, and macrophages in the
bronchial airway wall. In peripheral lung tissues the staining
of VEGF and receptors was analysed in the bronchiolar and
alveolar epithelium, bronchiolar ASM cells, and bronchiolar
and alveolar macrophages. The vasculature in the peripheral
lung was further subdivided into the larger pulmonary
vessels associated with the bronchiolar airways and smaller
vessels situated within the alveolar parenchyma. In each the
VEGF and receptor staining of endothelial, intimal, and
medial VSM cells was assessed. Since transforming growth
factor-b1 (TGF-b1) may also induce VEGF expression in
epithelial cells,25 26 we examined the correlation between the
epithelial VEGF expression in this study and the epithelial
TGF-b1 expression from one of our previous studies.
20 In both
studies the same patient groups were used and the staining
was performed on adjacent or near sections.
Statistical analysis
Data were analysed for statistical significance using the
unpaired two-tailed Student’s t test and the non-parametric
Mann-Whitney test where appropriate. Data on the expres-
sion of VEGF and its receptors were expressed as mean (SE).
The staining of VEGF and its receptors for different
compartments was correlated with FEV1 using Pearson’s
correlation analysis. Differences with p values of(0.05 were
considered statistically significant.
RESULTS
Clinical characteristics
The clinical and lung function characteristics of all subjects
included in the study are shown in table 1. As defined, the
COPD group had decreased FEV1 and FEV1/FVC values
(p,0.001), as has been described previously.19–23 The subjects
in the two groups did not differ significantly in age and
smoking status (pack years) or steroid use.
Immunolocalisation of VEGF, Flt-1, and KDR/Flk-1
Bronchial airways
Examples of VEGF expression in the central airways of non-
COPD and COPD subjects are shown in fig 1A and B, while
fig 1C and D (both taken from COPD subjects) show the
VEGF receptors and KDR/Flk-1, Flt-1 respectively. Within
the airways, VEGF, KDR/Flk-1 and Flt-1 were localised in the
bronchial epithelium and ASM cells, bronchial microvascu-
lature of the mucosa and submucosa, and on inflammatory
cells (predominantly macrophages) in all subjects (fig 1A–D).
In the vessel wall, VSM cells were positive for VEGF, Flt-1,
and KDR/Flk-1 while endothelial cells did not stain for VEGF
protein but were positive for Flt-1 and KDR/Flk-1 (fig 1).
To assess the intensities of VEGF, Flt-1, and KDR/Flk-1
expression in various bronchial airway compartments, a
visual scoring method was used as previously
described.8 19 20 23 VEGF expression was higher in the bron-
chial ASM cells of COPD patients than in those of non-COPD
subjects (1.6-fold, p,0.01) but not in bronchial epithelial
cells and macrophages (fig 2A). In the central airways of
patients with COPD, VEGF staining was more intense in the
VSM microvasculature of the bronchial mucosal (lamina
propria) (1.7-fold, p,0.001) and bronchial VSM in the
submucosa (1.4-fold, p,0.01, fig 2A) than in non-COPD
subjects. No significant differences were observed in the
levels of expression of KDR/Flk-1 and Flt-1 between COPD
and non-COPD subjects (fig 2B and C, respectively). In all
subjects VEGFR-2 (KDR/Flk-1) expression was more intense
than VEGFR-1 (Flt-1) expression, except in the endothelial
cells of bronchial microvessels and on bronchial macrophages
which were comparable (fig 2B and C).
Figure 1 Immunohistochemical localisation of (A, B) VEGF, (C) KDR/Flk-1, and (D) Flt-1 in bronchial tissues from non-COPD (ex-) smoking subjects
(A) and patients with COPD (B, C, D). Immunoreactive VEGF, KDR/Flk-1, and Flt-1 were localised in bronchial epithelial cells, airway smooth muscle
(ASM) cells, and in macrophages, endothelial and vascular smooth muscle (VSM) cells. Colour was developed with 3,3-diaminobenzidine
tetrahydrochloride (DAB) as chromogen (brown colour) and counterstained with Mayer’s haematoxylin. Arrows indicate sites of positivity for VEGF,
Flt-1 or KDR/Flk-1. Original magnification6100; scale bar =50 mm.
108 Kranenburg, Boer, Alagappan, et al
www.thoraxjnl.com
 on 25 October 2006 thorax.bmjjournals.comDownloaded from 
Bronchiolar airways
Figure 3 shows peripheral lung tissue from non-COPD and
COPD subjects stained for VEGF (fig 3A and B), KDR/Flk-1
(fig 3C and D), and Flt-1 (fig 3E and F). In bronchiolar
epithelial cells VEGF (1.5-fold, p,0.001, fig 4A) and Flt-1
expression (1.4-fold, p,0.04, fig 4C) were increased in COPD
patients compared with non-COPD subjects whereas the
staining for KDR/Flk-1 was unchanged in both patient
groups (fig 4B). ASM cells showed slightly increased VEGF
expression in the bronchiolar region (1.3-fold, p,0.05),
whereas the expression of both the receptors remained
unchanged in the two patient groups. However, the expres-
sion of KDR/Flk-1 was more intense than Flt-1 in all patients
(fig 4B and C). The increase in the expression of VEGF in the
larger pulmonary arteries associated with the bronchiolar
airways in the intimal and medial VSM cells was 1.7-fold and
1.3-fold, respectively (p,0.05, fig 4A) for COPD and control
subjects, while endothelial cells did not express VEGF. KDR/
Flk-1 expression was enhanced in endothelial cells and
intimal and medial VSM cells (1.3, 1.9 and 1.5-fold,
respectively, p,0.02, fig 4B); the corresponding value in
endothelial cells for Flt-1 expression was 1.7-fold (p,0.03,
fig 4C). In both patient groups the intimal VSM cells stained
2–3 times less intensely than medial VSM cells for VEGF, Flt-
1, and KDR/Flk-1. Moreover, vascular Flt-1 expression was
lower than KDR/Flk-1 and VEGF expression in each of the
investigated vessel wall areas (p,0.002, fig 4). VEGF staining
in bronchiolar macrophages (1.5-fold, p,0.001, fig 4A)
was higher in COPD subjects than in non-COPD subjects,
whereas the staining on macrophages of Flt-1 or KDR/Flk-1
expression in bronchiolar airways as well as VEGF, Flt-1,
or KDR/Flk-1 in the alveolar region remained unchanged
(fig 5).
Alveolar parenchyma
Staining of alveolar epithelial cells (type I and II) for COPD
was more intense than for non-COPD controls (1.5-fold,
p,0.0001, fig 5A). KDR/Flk-1 and Flt-1 expression were not
changed in alveolar epithelial cells (fig 5B and C). VEGF
expression was increased in intimal and medial VSM cells
(1.5 and 1.7-fold, p,0.01, fig 5A) of small pulmonary vessels
in the alveolar region; the corresponding values for KDR/Flk-
1 were 2.0 and 1.8-fold, respectively (p,0.02, fig 5B). The
expression of both KDR/Flk-1 and Flt-1 was increased in
endothelial cells of small pulmonary vessels in the lung
parenchyma (1.7 and 2.1-fold, respectively, p,0.001, fig 5B
and C).
Correlation between staining and clinical data
We examined the relationship between FEV1 values of
patients in both groups and the staining scores of VEGF,
Flt-1, and KDR/Flk-1 in the investigated areas. In the
bronchial airways FEV1 values were inversely correlated with
VEGF staining scores in the mucosal microvasculature
(r=20.65; p,0.001, fig 6A) and ASM cells (r=20.45;
p,0.01, fig 6B) if all subjects were analysed together. The
VEGF staining scores in the bronchiolar epithelium
(r=20.67; p,0.001, fig 6C) and medial VSM cells of larger
pulmonary arteries associated with the bronchiolar airways
(r=20.50; p,0.01, fig 6D) also showed an inverse correla-
tion with FEV1 values from the total group. In addition,
VEGF expression in the medial VSM cells was correlated with
KDR/Flk-1 expression in the endothelium of the pulmonary
arteries (r=0.41; p,0.01) as well as the smaller alveolar
vessels (r=0.48; p,0.01). Furthermore, we found correlation
for the expression pattern of KDR/Flk-1 and Flt-1 in the
endothelium of the pulmonary arteries (r=0.67; p,0.001) as
well as in alveolar vessels (r=0.80; p,0.0005).
We also examined the correlation between the epithelial
VEGF expression from the current study and epithelial TGF-
b1 expression from one of our previous studies.
20 In the
bronchiolar epithelium Pearson’s analysis revealed a signifi-
cant positive correlation between the levels of VEGF protein
and TGF-b1 protein (r=0.55; p,0.004) and between VEGF
protein levels and TGF-b1 mRNA expression (r=0.45;
p,0.02). In the alveolar epithelium VEGF protein levels
correlated significantly with TGF-b1 mRNA expression only
(r=0.58; p,0.002), but not with TGF-b1 protein levels
(r=0.31; p,0.12).
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Figure 2 Expression of (A) VEGF, (B) KDR/Flk-1 and (C) Flt-1 protein in
different cell types in bronchial airways using visual scoring. The
immunostaining score ranges from 0 (no staining) to 3 (very intense
staining). Open and closed bars represent mean data from subjects
without and with COPD, respectively. Data are presented as mean (SE).
Asterisk indicates a significant difference (p,0.05, Student’s t test)
compared with non-COPD subjects. Epi, bronchial epithelium; MV,
bronchial microvessels in the mucosa; VSM bron, bronchial vascular
smooth muscle cells in the submucosa; ASM, airway smooth muscle; Mw,
macrophages.
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DISCUSSION
The results of this study show that COPD is associated with
increased expression of VEGF in the bronchial, bronchiolar,
and alveolar epithelium and in bronchiolar macrophages as
well as ASM and VSM cells in both the bronchiolar and
alveolar regions. KDR/Flk-1 and Flt-1 were increased in
patients with COPD compared with non-COPD subjects in
endothelial, intimal and medial VSM cells of the larger
pulmonary arteries and of smaller calibre alveolar vessels.
Interestingly, we observed a significant inverse correlation
between VEGF and FEV1 in bronchial mucosal microvessels
and ASM cells, bronchiolar epithelium, and medial VSM cells
of the larger pulmonary arteries associated with the
bronchiolar airways. TGF-b1 staining in the bronchiolar
epithelium also correlated with VEGF in the same patients
as described in our previous study.20
Our results indicate that VEGF and its receptors Flt-1 and
KDR/Flk-1 are localised within the airways and vasculature
in endothelial and epithelial cells as well as smooth muscle
cells and, furthermore, on various inflammatory cells (pre-
dominantly macrophages). The localisation of VEGF and its
receptors in the lungs of our patient groups is in agreement
with earlier reports which described a similar staining pattern
in human developing lungs, normal adult lungs, and
emphysematous lungs.17 27 28 In contrast to Kasahara et al28
who showed that VEGF and its receptor VEGF-R2 were
decreased in total lung extracts of emphysematous lungs as
measured by ELISA or western blot analysis, we found that
the epithelial and endothelial cells in the alveolar spaces and
in the most distal airways were intensely positive for VEGF
and KDR/Flk-1 in patients with COPD. In our study the
patients could be considered as having mild to moderate
COPD whereas the lungs studied by Kasahara et al were solely
emphysematous.
Our findings of increased VEGF expression in viable cell
populations indicate in part a successful attempt to repair
sustained damage, and perhaps a contribution to vascular
remodelling and participation in the establishment and
maintenance of the functional blood-gas interface, matura-
tion, survival, and proliferation of capillary endothelial cells.29
In adult lungs VEGF and its receptor system may contribute
to the maintenance of endothelial and epithelial cell viability
in response to injury.31
Interestingly, immunoreactivity for VEGF in intimal and
medial VSM cells and for Flt-1 and KDR/Flk-1 in endothelial
cells of the pulmonary arteries and alveolar vessels was
increased in patients with COPD. The highest levels of VEGF
expression in the pulmonary vasculature were observed in
Figure 3 Immunohistochemical localisation of (A, B) VEGF, (C, D) KDR/Flk-1, and (E, F) Flt-1 in peripheral tissues from non-COPD (ex-) smoking
subjects (A, C, E) and patients with COPD (B, D, F). Immunoreactive VEGF, Flt-1, and KDR/Flk-1 were localised in bronchiolar and alveolar epithelial
cells, airway smooth muscle (ASM) cells, macrophages, and in endothelial and intimal/medial vascular smooth muscle (VSM) cells. Colour was
developed with 3,3-diaminobenzidine tetrahydrochloride (DAB) as chromogen (brown colour) and counterstained with Mayer’s haematoxylin. Arrows
indicate sites of positivity for VEGF, Flt-1, or KDR/Flk-1. Original magnification6100; scale bar = 50 mm.
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the medial VSM cells and of KDR/Flk-1 in endothelial cells of
arteries with a diameter of approximately 200 mm, which are
known to play an important role in pulmonary blood pressure
regulation and vascular resistance.14 30 Pulmonary hypoxia
and hypertension with increased sheer stress are pathophy-
siological conditions that have been shown to increase the
expression of VEGF in VSM cells.13 14 Blockade of KDR/Flk-1
is associated with obliterative endothelial cell proliferation in
pre-capillary arterioles with abnormal vessel development
and, at the same time, with induction of capillary endothelial
and cell death by apoptosis, together leading to death in rat
embryos similar to that seen in subjects with primary
pulmonary hypertension.13 18 31 32 In a follow up study Tuder
et al33 found that, after VEGFR-2 blockade, apoptosis pre-
dominated in areas of oxidative stress and apoptosis
blockade by a broad spectrum caspase inhibitor markedly
reduced the expression of markers of oxidative stress.33
Hypoxia, oxidative stress, and pulmonary hypertension are
pathological features often seen in patients with advanced
COPD, and increased VEGF expression may lead to increased
or even abnormal proliferation of endothelial and VSM cells
in pulmonary vessels. This suggests a potential role for this
endothelial mitogen in peripheral angiogenesis and vascular
remodelling, possibly in combination with other smooth
muscle specific growth factors such as FGF-2, PDGF, and
TGF-b1.
12 34–36
 

 




	
	









 	
	


  
	 


!" 



ϕ

#

$
%&
'



	
	


















	
	












    
	 

!" 
 ϕ
    
	 

!" 
 ϕ
Figure 4 Expression of (A) VEGF, (B) KDR/Flk-1, and (C) Flt-1 protein
in different cell types in bronchiolar airways and associated pulmonary
arteries using visual scoring. Open and closed bars represent mean data
from subjects without and with COPD, respectively. Data are presented
as mean (SE). Asterisk indicates a significant difference (p,0.05,
Student’s t test) compared with non-COPD subjects. Epi, bronchiolar
epithelium; EC, endothelial cells; VSM int, VSM med, intimal and medial
vascular smooth muscle cells; ASM, airway smooth muscle cells; Mw,
bronchiolar macrophages.
   

 



	








 
   ϕ









 
!

	








"	#
#
#
$
!%&
%&
     
   ϕ




'


!

	








#
#
#
     
   ϕ





#
Figure 5 Expression of (A) VEGF, (B) KDR/Flk-1, and (C) Flt-1 protein
in different cell types in alveolar parenchyma and pulmonary vasculature
using visual scoring. Open and closed bars represent mean data from
subjects without and with COPD, respectively. Data are presented as
mean (SE). Asterisk indicates a significant difference (p,0.05, Student’s
t test) compared with non-COPD subjects. Epi, bronchiolar epithelium;
EC, endothelial cells; VSM int, VSM med, intimal and medial vascular
smooth muscle cells; Mw, bronchiolar macrophages.
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We observed increased VEGF expression and unchanged
Flt-1 and KDR/Flk-1 expression in bronchiolar and alveolar
epithelial cells as well as in ASM cells in patients with COPD.
It has previously been reported that the expression of VEGF
and receptor KDR/Flk-1 can also be induced by stimuli such
as hypoxia and oxidative stress in cells other than endothelial
cells, such as epithelial and smooth muscle cells.33 37 38 In a
recent report Kanazawa and colleagues39 showed that VEGF
levels in induced sputum were higher in patients with
bronchitis and lower in those with emphysema than in
normal controls. Moreover, VEGF levels in patients with
bronchitis were inversely correlated with FEV1 values. Our
data on the inverse correlation of VEGF levels in various
airway and vascular cells is in agreement with this report. In
our study subjects with COPD could not be subdivided into
patients with either chronic bronchitis or emphysema alone.
Furthermore, the nature of the human material examined
(sputum) in the study by Kanazawa and colleagues is
different from the lung tissue in which we immunohisto-
chemically localised and quantified VEGF and its receptors.
Recent studies have indicated that VEGF expression is
increased in bronchial and alveolar epithelial cells and is also
induced in a-SMA positive (myo)fibroblasts in bleomycin
induced fibrosis in the rat and in human patients with
pulmonary fibrosis, and that these fibrotic regions are
densely populated by mast cells and macrophages with
increased KDR/Flk-1 expression.15 17 We have shown pre-
viously that mast cells and macrophages are increased in
bronchiolar airway epithelium and have reported increased
expression of TGF-b1 in bronchiolar and alveolar epithelial
cells in patients with COPD.20 21 We found a significant
correlation between VEGF expression in epithelial cells and
TGF-b1 expression published previously in the same patient
groups,20 which suggests that the VEGF/Flk-1 system—
possibly combined with TGF-b1—represents a molecular link
between inflammatory cell accumulation and proliferation of
myofibroblasts.
The increased expression of VEGF and TGF-b1 on
bronchiolar epithelial cells and macrophages and the
presence of KDR/Flk-1 and Flt-1 suggest a mechanism of
initiating and perpetuating fibrosis at sites of tobacco
induced injury contributing to airway remodelling in COPD.
Inhaled corticosteroids may decrease the levels of VEGF
expression,40 but this was not the case in our study as none of
the patients had received inhaled corticosteroid treatment
except four who received corticosteroids perioperatively.
Caution must be exercised in extrapolating the expression
data based on only 14 patients in each group, but the trend
for increased VEGF expression in bronchial airways and
KDR/Flk-1 in bronchial and bronchiolar airway smooth
muscle could reach significance if more patients were
included.
Taken together, these findings strongly suggest a role for
VEGF and its receptors in airway and vascular remodelling,
and thereby in the development of airway obstruction in
COPD. At present our knowledge of airway and vascular
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Figure 6 Correlation with FEV1 (% predicted) of VEGF protein expression in (A) microvessels (MV) in the bronchial mucosa, (B) bronchial airway
smooth muscle (ASM) cells, (C) bronchiolar epithelial (Epi) cells, and (D) medial vascular smooth muscle (VSM) cells of pulmonary arteries associated
with the bronchiolar airways. Correlation was assessed for the combined patient groups (non-COPD and COPD). The correlation coefficient (r) was
obtained using linear regression (Pearson’s) analysis.
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remodelling during the development of COPD is far from
complete. It is probable that many growth factors—including
VEGF—play an essential role in the pulmonary and vascular
viability and repair in response to tissue injury. Increased
pulmonary VEGF expression in the airways, parenchymal
lining, and small diameter pulmonary vessels in COPD may
reflect a partly unsuccessful attempt to stimulate tissue repair
mechanisms caused by tobacco induced injury.
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